Publicacións en colaboración con investigadores/as de University of Sheffield (26)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  2. Repeated Bilateral Transcranial Direct Current Stimulation over Auditory Cortex for Tinnitus Treatment: A Double-Blinded Randomized Controlled Clinical Trial

    Brain Sciences, Vol. 14, Núm. 4

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

2017

  1. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

    The Lancet Oncology, Vol. 18, Núm. 2, pp. 181-191

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Identification and characterization of novel variations in platelet G-protein coupled receptor (GPCR) genes in patients historically diagnosed with type 1 von Willebrand disease

    PLoS ONE, Vol. 10, Núm. 12

2014

  1. A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 12, pp. 2130-2136

  2. Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies

    Arthritis and Rheumatology, Vol. 66, Núm. 4, pp. 940-949

2013

  1. Mineralization of porous hydrogels based on semi-interpenetrated networks of poly[2-ethyl(2-pyrrolidone) methacrylate] and hyaluronic acid in simulated body fluid

    Journal of Bioactive and Compatible Polymers, Vol. 28, Núm. 5, pp. 468-480

  2. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease

    Blood, Vol. 121, Núm. 12, pp. 2336-2339

2011

  1. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease

    Haemophilia

  2. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 5, pp. 864-867

2010

  1. The impact of bleeding history, von willebrand factor and PFA-100® on the diagnosis of type 1 von willebrand disease: Results from the european study MCMDM-1VWD

    British Journal of Haematology, Vol. 151, Núm. 3, pp. 245-251

  2. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD

    Thrombosis Research, Vol. 126, Núm. 3, pp. 227-231

2009

  1. Expression of 14 von Willebrand factor mutations identified in patients with type.1 von Willebrand disease from the MCMDM-1VWD study

    Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 8, pp. 1304-1312

2008

  1. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)

    Journal of Thrombosis and Haemostasis, Vol. 6, Núm. 5, pp. 762-771

  2. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the european study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)

    Blood, Vol. 111, Núm. 10, pp. 4979-4985

  3. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the European Study MCMDM-1VWD

    Blood, Vol. 111, Núm. 7, pp. 3531-3539